Disclaimer

● As some programs are still confidential, some candidates may not be identified in this list. In these materials, Pfizer discloses Mechanism of Action (MOA) information for some candidates in Phase 1 and for all candidates from Phase 2 through regulatory approval. With a view to expanding the transparency of our pipeline, Pfizer is including new indications or enhancements, which target unmet medical need or represent significant commercial opportunities. The information contained on these pages is correct as of April 28, 2020.

● Visit Pfizer.com/pipeline, Pfizer’s online database where you can learn more about our portfolio of new medicines and find out more about our Research and Development efforts around the world.
# Table of Contents

- Pfizer Pipeline Snapshot 4
- Inflammation and Immunology 5-6
- Internal Medicine 7
- Oncology 8-10
- Rare Diseases 11
- Vaccines 12
- Hospital (Anti-Infectives) 13
- Programs Discontinued Since Last Update 14
- Backup: Regulatory Designation Definitions 15-16
### Pfizer Pipeline Snapshot as of April 28, 2020

**Discovery Projects**
- **Phase 1:** 27
- **Phase 2:** 37
- **Phase 3:** 21
- **Registration:** 6
- **Total:** 91

**Recent Approvals**
- AMSPARITY® (adalimumab), as a biosimilar to Humira® (adalimumab) for the treatment of certain patients with rheumatoid arthritis, juvenile idiopathic arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis, hidradenitis suppurativa, Crohn’s disease, ulcerative colitis, uveitis, and pediatric plaque psoriasis (E.U.)
- BRAFTOVIR® (encorafenib) in combination with Erbitux® (cetuximab) for the treatment of BRAF V600E-mutant metastatic colorectal cancer after prior therapy (U.S.)
- RUXIENCE® (rituximab), as a biosimilar to MabThera® (rituximab) for the treatment of non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis and microscopic polyangiitis, and pemphigus vulgaris (E.U.)
- STAQUIS® (crisaborole) for the treatment of mild to moderate atopic dermatitis in adults and pediatric patients from 2 years of age with ≤40% body surface area affected (E.U.)
- VYNDACEL® (tafamidis free acid) a once-daily 61 mg oral capsule, for the treatment of wild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (E.U.)

### Pfizer Pipeline Snapshot as of January 28, 2020

**Discovery Projects**
- **Phase 1:** 26
- **Phase 2:** 37
- **Phase 3:** 23
- **Registration:** 9
- **Total:** 95

**Recent Approvals**
- XTANDI® (enzalutamide) for the treatment of patients with metastatic castration-sensitive prostate cancer (U.S.)
- ABRLADA® (adalimumab-afzb), as a biosimilar to Humira® (adalimumab), for the treatment of certain patients with rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn’s disease, ulcerative colitis and plaque psoriasis (U.S.)
- XELJANZ® (tofacitinib) prolonged release in combination with methotrexate for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (E.U.)

---

1. Humira® is a registered U.S. trademark of Abbvie Biotechnology Ltd.
2. Erbitux® is a registered trademark of ImClone LLC.
3. MabThera® is a registered trademark of Roche, Inc.
## Inflammation and Immunology (1 of 2)

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Mechanism of Action</th>
<th>Indication</th>
<th>Phase of Development</th>
<th>Submission Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>abrocitinib (PF-04965842)</td>
<td>JAK Inhibitor</td>
<td>Atopic Dermatitis (BREAKTHROUGH)</td>
<td>Phase 3</td>
<td>New Molecular Entity</td>
</tr>
<tr>
<td>ritlecitinib (PF-06651600)</td>
<td>JAK3/TEC Inhibitor</td>
<td>Alopecia Areata (BREAKTHROUGH)</td>
<td>Phase 3</td>
<td>New Molecular Entity</td>
</tr>
<tr>
<td>Xeljanz (tofacitinib)</td>
<td>JAK Inhibitor</td>
<td>Ankylosing Spondylitis</td>
<td>Phase 3</td>
<td>Product Enhancement</td>
</tr>
<tr>
<td>Dekavil</td>
<td>IL-10</td>
<td>Rheumatoid Arthritis (Biologic)</td>
<td>Phase 2</td>
<td>New Molecular Entity</td>
</tr>
<tr>
<td>Dekavil</td>
<td>IL-10</td>
<td>Ulcerative Colitis (Biologic)</td>
<td>Phase 2</td>
<td>Product Enhancement</td>
</tr>
<tr>
<td>PF-06480605</td>
<td>TNFSF15 Blocker</td>
<td>Ulcerative Colitis (Biologic)</td>
<td>Phase 2</td>
<td>New Molecular Entity</td>
</tr>
<tr>
<td>PF-06650833</td>
<td>IRAK4 Inhibitor</td>
<td>Rheumatoid Arthritis</td>
<td>Phase 2</td>
<td>New Molecular Entity</td>
</tr>
<tr>
<td>ritlecitinib (PF-06651600)</td>
<td>JAK3/TEC Inhibitor</td>
<td>Rheumatoid Arthritis</td>
<td>Phase 2</td>
<td>Product Enhancement</td>
</tr>
<tr>
<td>PF-06650833</td>
<td>IRAK4 Inhibitor TYK2/JAK1 Inhibitor</td>
<td>Hidradenitis Suppurativa</td>
<td>Phase 2</td>
<td>Product Enhancement</td>
</tr>
<tr>
<td>brepocitinib (PF-06700841)</td>
<td>JAK3/TEC Inhibitor TYK2/JAK1 Inhibitor</td>
<td>Ulcerative Colitis</td>
<td>Phase 2</td>
<td>New Molecular Entity</td>
</tr>
<tr>
<td>ritlecitinib (PF-06651600)</td>
<td>JAK3/TEC Inhibitor TYK2/JAK1 Inhibitor</td>
<td>Crohn's Disease</td>
<td>Phase 2</td>
<td>Product Enhancement</td>
</tr>
<tr>
<td>ritlecitinib (PF-06651600)</td>
<td>JAK3/TEC Inhibitor TYK2/JAK1 Inhibitor</td>
<td>Vitiligo</td>
<td>Phase 2</td>
<td>Product Enhancement</td>
</tr>
<tr>
<td>brepocitinib (PF-06700841)</td>
<td>TYK2/JAK1 Inhibitor</td>
<td>Psoriatic Arthritis</td>
<td>Phase 2</td>
<td>Product Enhancement</td>
</tr>
</tbody>
</table>

*Regulatory Designations – See Definitions in Backup*
## Inflammation and Immunology (2 of 2)

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Mechanism of Action</th>
<th>Indication</th>
<th>Phase of Development</th>
<th>Submission Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>brepocitinib (PF-06700841)</td>
<td>TYK2/JAK1 Inhibitor</td>
<td>Alopecia Areata</td>
<td>Phase 2</td>
<td>Product Enhancement</td>
</tr>
<tr>
<td>brepocitinib (PF-06700841)</td>
<td>TYK2/JAK1 Inhibitor</td>
<td>Lupus</td>
<td>Phase 2</td>
<td>Product Enhancement</td>
</tr>
<tr>
<td>brepocitinib (PF-06700841)</td>
<td>Topical TYK2/JAK1 Inhibitor</td>
<td>Atopic Dermatitis</td>
<td>Phase 2</td>
<td>New Molecular Entity</td>
</tr>
<tr>
<td>brepocitinib (PF-06700841)</td>
<td>Topical TYK2/JAK1 Inhibitor</td>
<td>Psoriasis</td>
<td>Phase 2</td>
<td>New Molecular Entity</td>
</tr>
<tr>
<td>PF-06823859 interferon, beta 1, fibroblast (IFNB1) Blocker</td>
<td>Inflammatory Disorders (Biologic)</td>
<td>Phase 2</td>
<td>New Molecular Entity</td>
<td></td>
</tr>
<tr>
<td>PF-06826647 TYK2 Inhibitor</td>
<td>Psoriasis</td>
<td>Phase 2</td>
<td>New Molecular Entity</td>
<td></td>
</tr>
<tr>
<td>PF-06826647 TYK2 Inhibitor</td>
<td>Ulcerative Colitis</td>
<td>Phase 1</td>
<td>Product Enhancement</td>
<td></td>
</tr>
<tr>
<td>PF-06835375 Chemokine Inhibitor</td>
<td>Lupus (Biologic)</td>
<td>Phase 1</td>
<td>New Molecular Entity</td>
<td></td>
</tr>
<tr>
<td>PF-07038124 Topical PDE4 Inhibitor</td>
<td>Atopic Dermatitis</td>
<td>Phase 1</td>
<td>New Molecular Entity</td>
<td></td>
</tr>
</tbody>
</table>
### Internal Medicine

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Mechanism of Action</th>
<th>Indication</th>
<th>Phase of Development</th>
<th>Submission Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>tanezumab</td>
<td>Nerve Growth Factor Inhibitor</td>
<td>Chronic Pain due to Moderate-to-Severe Osteoarthritis (OA) (Biologic) (U.S., E.U.)</td>
<td>Registration</td>
<td>New Molecular Entity</td>
</tr>
<tr>
<td>tanezumab</td>
<td>Nerve Growth Factor Inhibitor</td>
<td>Cancer Pain, Chronic Low Back Pain (Biologic)</td>
<td>Phase 3</td>
<td>Product Enhancement</td>
</tr>
<tr>
<td>PF-06835919</td>
<td>Ketohexokinase (KHK) Inhibitor</td>
<td>Non-Alcoholic Steatohepatitis (NASH) with Liver Fibrosis</td>
<td>Phase 2</td>
<td>New Molecular Entity</td>
</tr>
<tr>
<td>PF-07055341</td>
<td>ACCi and DGAT2 Combination</td>
<td>Combo of PF-05221304 and PF-06865571 for Non-Alcoholic Steatohepatitis (NASH) with Liver Fibrosis</td>
<td>Phase 2</td>
<td>New Molecular Entity</td>
</tr>
<tr>
<td>PF-05221304</td>
<td>Acetyl CoA-Carboxylase (ACC) Inhibitor</td>
<td>Non-Alcoholic Steatohepatitis (NASH) with Liver Fibrosis (FAST TRACK)</td>
<td>Phase 2</td>
<td>New Molecular Entity</td>
</tr>
<tr>
<td>vupanorsen</td>
<td>Angiopoietin Like 3 (ANGPTL3)</td>
<td>Cardiovascular Risk Reduction, Severe Hypertriglyceridemia</td>
<td>Phase 2</td>
<td>New Molecular Entity</td>
</tr>
<tr>
<td>PF-06865571</td>
<td>Diacylglycerol O-Acyltransferase 2 (DGAT2) Inhibitor</td>
<td>Non-Alcoholic Steatohepatitis (NASH) with Liver Fibrosis</td>
<td>Phase 1</td>
<td>New Molecular Entity</td>
</tr>
<tr>
<td>PF-06882961</td>
<td>Glucagon-like peptide 1 receptor (GLP-1R) Agonist</td>
<td>Diabetes Mellitus-Type 2 and Obesity</td>
<td>Phase 1</td>
<td>New Molecular Entity</td>
</tr>
<tr>
<td>PF-06946860</td>
<td>Growth Differentiation Factor 15 (GDF15) Monoclonal Antibody</td>
<td>Cachexia (Biologic)</td>
<td>Phase 1</td>
<td>New Molecular Entity</td>
</tr>
<tr>
<td>PF-06842874</td>
<td>CDK 4,6 Inhibitor</td>
<td>Pulmonary Arterial Hypertension</td>
<td>Phase 1</td>
<td>New Molecular Entity</td>
</tr>
<tr>
<td>PF-07081532</td>
<td>Glucagon-like peptide 1 receptor (GLP-1R) Agonist</td>
<td>Diabetes Mellitus-Type 2 and Obesity</td>
<td>Phase 1</td>
<td>New Molecular Entity</td>
</tr>
</tbody>
</table>

► Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer.com

• Regulatory Designations – See Definitions in Backup
# Oncology (1 of 3)

![Bar chart showing phases of development](chart)

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Mechanism of Action</th>
<th>Indication</th>
<th>Phase of Development</th>
<th>Submission Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>PF-06881894, a potential biosimilar to Neulasta® (pegfilgrastim)</td>
<td>Human Granulocyte Colony Stimulating Factor</td>
<td>Neutropenia in patients undergoing cancer chemotherapy (Biosimilar) (U.S., E.U.)</td>
<td>Registration</td>
<td>Biosimilar</td>
</tr>
<tr>
<td>Daurismo (glasdegib)</td>
<td>SMO (smoothened) antagonist</td>
<td>Combo w/low-dose cytarabine (LDAC) for Acute Myeloid Leukemia (E.U.)</td>
<td>Registration</td>
<td>New Molecular Entity</td>
</tr>
<tr>
<td>Xtandi (enzalutamide)</td>
<td>Androgen receptor inhibitor</td>
<td>Metastatic Hormone Sensitive Prostate Cancer (E.U.)</td>
<td>Registration</td>
<td>Product Enhancement</td>
</tr>
<tr>
<td>Braftovi (encorafinib) + Erbitux® (cetuximab)</td>
<td>BRAF kinase inhibitor</td>
<td>2nd or 3rd Line BRAF-mutant Metastatic Colorectal Cancer (E.U.)</td>
<td>Registration</td>
<td>Product Enhancement</td>
</tr>
<tr>
<td>▶ Bavencio (avelumab)</td>
<td>Anti PD-L1</td>
<td>1st Line Urothelial Cancer (Biologic) (BREAKTHROUGH - U.S)¹</td>
<td>Registration</td>
<td>Product Enhancement</td>
</tr>
<tr>
<td>Bavencio (avelumab)</td>
<td>Anti PD-L1</td>
<td>1st Line Urothelial Cancer (Biologic)</td>
<td>Phase 3</td>
<td>Product Enhancement</td>
</tr>
<tr>
<td>Bavencio (avelumab)</td>
<td>Anti PD-L1</td>
<td>1st Line Non-Small Cell Lung Cancer (Biologic)</td>
<td>Phase 3</td>
<td>Product Enhancement</td>
</tr>
<tr>
<td>Daurismo (glasdegib)</td>
<td>SMO (smoothened) antagonist</td>
<td>Combo w/azacytidine in Acute Myeloid Leukemia (ORPHAN - U.S., E.U.)</td>
<td>Phase 3</td>
<td>Product Enhancement</td>
</tr>
<tr>
<td>Ibrance (palbociclib)</td>
<td>CDK 4,6 kinase inhibitor</td>
<td>High Risk Early Breast Cancer</td>
<td>Phase 3</td>
<td>Product Enhancement</td>
</tr>
<tr>
<td>Ibrance (palbociclib)</td>
<td>CDK 4,6 kinase inhibitor</td>
<td>Early Breast Cancer in Adjuvant Setting</td>
<td>Phase 3</td>
<td>Product Enhancement</td>
</tr>
</tbody>
</table>

¹ - Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer.com

- Being reviewed under FDA Real-Time Oncology Review (RTOR) Pilot Program
- Regulatory Designations – See Definitions in Backup
- Neulasta® is a registered U.S. trademark of Amgen Inc.
- Erbitux® is a registered trademark of ImClone LLC

**Breakthroughs that change patients’ lives**
<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Mechanism of Action</th>
<th>Indication</th>
<th>Phase of Development</th>
<th>Submission Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>PF-06801591 + Bacillus Calmette-Guerin (BCG)</td>
<td>Anti-PD-1</td>
<td>Non-Muscle-Invasive Bladder Cancer (Biologic)</td>
<td>Phase 3</td>
<td>New Molecular Entity</td>
</tr>
<tr>
<td>Ibrance (palbociclib)</td>
<td>CDK 4,6 kinase inhibitor</td>
<td>ER+/HER2+ Breast Cancer</td>
<td>Phase 3</td>
<td>Product Enhancement</td>
</tr>
<tr>
<td>Lorbrena (lorlatinib)</td>
<td>ALK inhibitor</td>
<td>1st Line ALK Non-Small Cell Lung Cancer (ORPHAN - U.S.)</td>
<td>Phase 3</td>
<td>Product Enhancement</td>
</tr>
<tr>
<td>Talzenna (talazoparib)</td>
<td>PARP inhibitor</td>
<td>Combo w/ Xtandi (enzalutamide) for 1st Line Metastatic Castration-Resistant Prostate Cancer</td>
<td>Phase 3</td>
<td>Product Enhancement</td>
</tr>
<tr>
<td>Xtandi (enzalutamide)</td>
<td>Androgen receptor inhibitor</td>
<td>Non-metastatic High Risk Hormone Sensitive Prostate Cancer</td>
<td>Phase 3</td>
<td>Product Enhancement</td>
</tr>
<tr>
<td>Bavencio (avelumab)</td>
<td>Anti PD-L1</td>
<td>1st Line Merkel Cell Carcinoma (Biologic)</td>
<td>Phase 2</td>
<td>Product Enhancement</td>
</tr>
<tr>
<td>Bavencio (avelumab)</td>
<td>Anti PD-L1</td>
<td>Combo w/CMP-001 for Head and Neck Cancer</td>
<td>Phase 2</td>
<td>Product Enhancement</td>
</tr>
<tr>
<td>Bavencio (avelumab)</td>
<td>Anti PD-L1</td>
<td>Combo w/Talzenna (talazoparib) for Locally Advanced (Primary or Recurrent) or Metastatic Solid Tumors (Biologic)</td>
<td>Phase 2</td>
<td>Product Enhancement</td>
</tr>
<tr>
<td>Bavencio (avelumab)</td>
<td>Anti PD-L1</td>
<td>Combo w/Talzenna (talazoparib) for Solid Tumors with a BRCA or ATM defect (Biologic)</td>
<td>Phase 2</td>
<td>Product Enhancement</td>
</tr>
<tr>
<td>Braftovi (encorafenib) + Mektovi (binimetinib)</td>
<td>BRAF kinase inhibitor and MEK inhibitor</td>
<td>BRAF-mutant Metastatic Melanoma (ORPHAN - U.S.)</td>
<td>Phase 2</td>
<td>Product Enhancement</td>
</tr>
<tr>
<td>Braftovi (encorafenib) + Mektovi (binimetinib)</td>
<td>BRAF kinase inhibitor and MEK inhibitor</td>
<td>1st line BRAF-mutant Colorectal Cancer</td>
<td>Phase 2</td>
<td>Product Enhancement</td>
</tr>
<tr>
<td>Braftovi (encorafenib) + Mektovi (binimetinib)</td>
<td>BRAF kinase inhibitor and MEK inhibitor</td>
<td>1st line BRAF-mutant Non-Small Cell Lung Cancer</td>
<td>Phase 2</td>
<td>Product Enhancement</td>
</tr>
<tr>
<td>Daurismo (glasdegib)</td>
<td>SMO (smoothened) antagonist</td>
<td>Myelodysplastic Syndrome</td>
<td>Phase 2</td>
<td>Product Enhancement</td>
</tr>
<tr>
<td>Talzenna (talazoparib)</td>
<td>PARP inhibitor</td>
<td>2nd Line Metastatic Castration-Resistant Prostate Cancer</td>
<td>Phase 2</td>
<td>Product Enhancement</td>
</tr>
<tr>
<td>Talzenna (talazoparib)</td>
<td>PARP inhibitor</td>
<td>Germline BRCA Mutated Locally Advanced Triple Negative Breast Cancer</td>
<td>Phase 2</td>
<td>Product Enhancement</td>
</tr>
</tbody>
</table>

• Regulatory Designations – See Definitions in Backup
<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Mechanism of Action</th>
<th>Indication</th>
<th>Phase of Development</th>
<th>Submission Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bavencio (avelumab)</td>
<td>Anti PD-L1</td>
<td>Combo w/Talzenna (talazoparib) and binimetinib for Solid Tumors (Biologic)</td>
<td>Phase 1</td>
<td>Product Enhancement</td>
</tr>
<tr>
<td>Bavencio (avelumab)</td>
<td>Anti PD-L1</td>
<td>Cancer (Biologic)</td>
<td>Phase 1</td>
<td>Product Enhancement</td>
</tr>
<tr>
<td>PF-05082566</td>
<td>CD137 Agonist</td>
<td>Combo w/Kite Pharma’s Yescarta® (axicabtagene ciloleucel) for Cancer</td>
<td>Phase 1</td>
<td>New Molecular Entity</td>
</tr>
<tr>
<td>PF-06647020</td>
<td>protein tyrosine kinase 7 (PTK7) Targeted Cytotoxicity</td>
<td>Cancer (Biologic)</td>
<td>Phase 1</td>
<td>New Molecular Entity</td>
</tr>
<tr>
<td>PF-06804103</td>
<td>HER2 Antibody Drug Conjugate</td>
<td>Cancer (Biologic)</td>
<td>Phase 1</td>
<td>New Molecular Entity</td>
</tr>
<tr>
<td>PF-06821497</td>
<td>EZH2 inhibitor</td>
<td>Cancer</td>
<td>Phase 1</td>
<td>New Molecular Entity</td>
</tr>
<tr>
<td>PF-06863135</td>
<td>BCMA-CD3 Bispecific Antibody</td>
<td>Multiple Myeloma (Biologic)</td>
<td>Phase 1</td>
<td>New Molecular Entity</td>
</tr>
<tr>
<td>PF-06873600</td>
<td>CDK 2,4,6 inhibitor</td>
<td>Breast Cancer Metastatic</td>
<td>Phase 1</td>
<td>New Molecular Entity</td>
</tr>
<tr>
<td>PF-06952229</td>
<td>transforming growth factor, beta receptor 1 (TGFBR1) Inhibitor</td>
<td>Cancer</td>
<td>Phase 1</td>
<td>New Molecular Entity</td>
</tr>
<tr>
<td>PF-06939999</td>
<td>protein arginine methyltransferase 5 (PRMT5) Inhibitor</td>
<td>Solid Tumors</td>
<td>Phase 1</td>
<td>New Molecular Entity</td>
</tr>
<tr>
<td>PF-07062119</td>
<td>GUCY2c CD3 Bispecific Antibody</td>
<td>Solid Tumors (Biologic)</td>
<td>Phase 1</td>
<td>New Molecular Entity</td>
</tr>
<tr>
<td>PF-06940434</td>
<td>Integrin alpha-V/beta-8 Antagonist</td>
<td>Solid Tumors (Biologic)</td>
<td>Phase 1</td>
<td>New Molecular Entity</td>
</tr>
<tr>
<td>PF-06753512</td>
<td>Therapeutic Vaccine</td>
<td>Prostate Cancer</td>
<td>Phase 1</td>
<td>New Molecular Entity</td>
</tr>
<tr>
<td>PF-06936308</td>
<td>Therapeutic Vaccine</td>
<td>Multiple Cancers</td>
<td>Phase 1</td>
<td>New Molecular Entity</td>
</tr>
</tbody>
</table>

* Yescarta® is a registered U.S. trademark of Kite Pharma, Inc.
## Rare Diseases

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Mechanism of Action</th>
<th>Indication</th>
<th>Phase of Development</th>
<th>Submission Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>PF-07265803</td>
<td>p38 Mitogen-Activated Protein Kinase</td>
<td>Dilated Cardiomyopathy due To Lamin A/C Gene Mutation</td>
<td>Phase 3</td>
<td>New Molecular Entity</td>
</tr>
<tr>
<td>fidanacogene elaparvovec (PF-06838435)</td>
<td>Gene Therapy, coagulation factor IX (F9)</td>
<td>Hemophilia (Biologic) (BREAKTHROUGH, ORPHAN - U.S., E.U., PRIME - E.U.)</td>
<td>Phase 3</td>
<td>New Molecular Entity</td>
</tr>
<tr>
<td>somatogon (PF-06836922)</td>
<td>Human Growth Hormone Agonist</td>
<td>Pediatric Growth Hormone Deficiency (Biologic) (ORPHAN - U.S., E.U.)</td>
<td>Phase 3</td>
<td>New Molecular Entity</td>
</tr>
<tr>
<td>somatogon (PF-06836922)</td>
<td>Human Growth Hormone Agonist</td>
<td>Adult Growth Hormone Deficiency (Biologic) (ORPHAN - U.S., E.U.)</td>
<td>Phase 3</td>
<td>New Molecular Entity</td>
</tr>
<tr>
<td>giroctocogene fitelparvovec (PF-07055480)</td>
<td>AAV-FVIII GTx</td>
<td>Hemophilia (Biologic) (RMAT, FAST TRACK, ORPHAN - U.S.; ORPHAN – E.U.)</td>
<td>Phase 2</td>
<td>New Molecular Entity</td>
</tr>
<tr>
<td>PF-06730512</td>
<td>SLIT2 antagonist</td>
<td>Focal Segmental Glomerulosclerosis (FSGS) (Biologic)</td>
<td>Phase 2</td>
<td>New Molecular Entity</td>
</tr>
<tr>
<td>marstacimab (PF-06741086)</td>
<td>Tissue Factor Pathway Inhibitor (TFPI)</td>
<td>Hemophilia (Biologic) (FAST TRACK – U.S.; ORPHAN - U.S., E.U.)</td>
<td>Phase 2</td>
<td>New Molecular Entity</td>
</tr>
<tr>
<td>PF-06755347</td>
<td>Immunomodulation</td>
<td>Chronic Inflammatory Demyelination Polyneuropathy</td>
<td>Phase 1</td>
<td>New Molecular Entity</td>
</tr>
<tr>
<td>PF-06939926</td>
<td>Gene Therapy, minidystrophin</td>
<td>Duchenne Muscular Dystrophy (Biologic) (ORPHAN - U.S., E.U.)</td>
<td>Phase 1</td>
<td>New Molecular Entity</td>
</tr>
<tr>
<td>recifercept</td>
<td>Soluble recombinant human fibroblast growth factor receptor 3 (FGFR3) decoy</td>
<td>Achondroplasia (Biologic)</td>
<td>Phase 1</td>
<td>New Molecular Entity</td>
</tr>
<tr>
<td>►PF-07209326</td>
<td>E-Selectin Protein-Protein Interaction Inhibitor</td>
<td>Sickle Cell Disease (Biologic)</td>
<td>Phase 1</td>
<td>New Molecular Entity</td>
</tr>
</tbody>
</table>

► Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer.com
1 - Lead-in trial of the Phase 3 clinical program ongoing
* Regulatory Designations – See Definitions in Backup
## Vaccines

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Mechanism of Action</th>
<th>Indication</th>
<th>Phase of Development</th>
<th>Submission Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>PF-06425090</td>
<td>Prophylactic Vaccine</td>
<td>Primary <em>clostridioides difficile</em> infection (FAST TRACK)</td>
<td>Phase 3</td>
<td>New Molecular Entity</td>
</tr>
<tr>
<td>PF-06482077</td>
<td>Prophylactic Vaccine</td>
<td>Invasive and Non-Invasive Pneumococcal infections (Adult) (BREAKTHROUGH)</td>
<td>Phase 3</td>
<td>New Molecular Entity</td>
</tr>
<tr>
<td>PF-06842433</td>
<td>Prophylactic Vaccine</td>
<td>Invasive and Non-Invasive Pneumococcal infections (infants and children)</td>
<td>Phase 2</td>
<td>New Molecular Entity</td>
</tr>
<tr>
<td>PF-06760805</td>
<td>Prophylactic Vaccine</td>
<td>Invasive Group B Streptococcus Infection (maternal)</td>
<td>Phase 2</td>
<td>New Molecular Entity</td>
</tr>
<tr>
<td>PF-06886992</td>
<td>Prophylactic Vaccine</td>
<td>Serogroups ABCWY Meningococcal Infections (adolescent and young adults)</td>
<td>Phase 2</td>
<td>New Molecular Entity</td>
</tr>
<tr>
<td>PF-06928316</td>
<td>Prophylactic Vaccine</td>
<td>Respiratory Syncytial Virus Infection (maternal)</td>
<td>Phase 2</td>
<td>New Molecular Entity</td>
</tr>
<tr>
<td>►PF-07302048 (BNT162)</td>
<td>Prophylactic mRNA Vaccine</td>
<td>COVID-19 Infection (in partnership with BioNTech)</td>
<td>Phase 1</td>
<td>New Molecular Entity</td>
</tr>
</tbody>
</table>

► Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer.com

• Regulatory Designations – See Definitions in Backup
<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Mechanism of Action</th>
<th>Indication</th>
<th>Phase of Development</th>
<th>Submission Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>aztreonam-avibactam (PF-06947387)</td>
<td>Beta Lactam/Beta Lactamase Inhibitor</td>
<td>Treatment of infections caused by Gram-negative bacteria for which there are limited or no treatment options</td>
<td>Phase 3</td>
<td>New Molecular Entity</td>
</tr>
<tr>
<td>PF-00835231</td>
<td>SARS-CoV-2 3CL protease inhibitor</td>
<td>COVID-19 Infection</td>
<td>Pre-clinical¹</td>
<td>New Molecular Entity</td>
</tr>
</tbody>
</table>

¹ Including pre-clinical program, as an exception, to provide transparency into our efforts in combating COVID-19
<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Mechanism of Action</th>
<th>Indication</th>
<th>Phase of Development</th>
<th>Submission Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vyndaqel (tafamidis meglumine)</td>
<td>Transthyretin (TTR) Dissociation Inhibitor</td>
<td>Transthyretin familial amyloid polyneuropathy (U.S.)</td>
<td>Registration</td>
<td>New Molecular Entity</td>
</tr>
<tr>
<td>rivipansel (GMI-1070)</td>
<td>Pan-Selectin Antagonist</td>
<td>Acute vaso-occlusive crises associated with sickle cell disease in patients aged 6 years and above</td>
<td>Phase 3</td>
<td>New Molecular Entity</td>
</tr>
<tr>
<td>Bavencio (avelumab)</td>
<td>Anti PD-L1</td>
<td>Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Biologic)</td>
<td>Phase 3</td>
<td>Product Enhancement</td>
</tr>
<tr>
<td>PF-05230907</td>
<td>Factor Xa Protein Replacement</td>
<td>Intracerebral Hemorrhage (Biologic)</td>
<td>Phase 1</td>
<td>New Molecular Entity</td>
</tr>
</tbody>
</table>
Back-up
Regulatory Designations

- **Fast Track (U.S.)** is a designation available to a product if it is intended, whether alone or in combination with one or more other drugs, for the treatment of a serious or life-threatening disease or condition, and it demonstrates the potential to address unmet medical needs for such a disease or condition. This designation is intended to facilitate development and expedite review of drugs to treat serious and life-threatening conditions so that an approved product can reach the market expeditiously. More information about the qualifying criteria and features of the Fast Track program can be found on the FDA’s website.

- **Breakthrough Designation (U.S.)** may be granted to a drug (alone or in combination with 1 or more other drugs) intended to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. A drug that receives breakthrough designation is eligible for all fast track designation features and an FDA commitment to work closely with the sponsor to ensure an efficient drug development program. More information about the qualifying criteria and features of the Breakthrough program can be found on the FDA’s website.

- **Orphan Drug (U.S.)** - Orphan drug status may be granted to drugs and biologics that are intended for the diagnosis, prevention, or treatment of rare diseases/disorders that affect fewer than 200,000 people in the U.S., or that affect more than 200,000 persons but where it is unlikely that expected sales of the product would cover the sponsor’s investment in its development. More information about the qualifying criteria, features, and incentives involved in an orphan drug designation can be found on the FDA’s website.

- **Orphan Drug (E.U.)** - Orphan drug status may be granted to drugs and biologics that are intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition affecting no more than 5 in 10,000 persons in the European Union at the time of submission of the designation application, or that affect more than 5 in 10,000 persons but where it is unlikely that expected sales of the product would cover the investment in its development. More information about the qualifying criteria, features, and incentives involved in an orphan drug designation can be found on the EMA’s website.

- A U.S. drug application will receive a **priority review designation** if it is for a drug that treats a serious condition and, if approved, would provide a significant improvement in safety or effectiveness. A priority designation is intended to direct overall attention and resources to the evaluation of such applications. A priority review designation means that FDA’s goal is to take action on the marketing application within 6 months of receipt (compared with 10 months under standard review). More information about the qualifying criteria and features of a priority review designation can be found on the FDA’s website.

- **PRIME (E.U.)** - The PRIME scheme is applicable to products under development which are innovative and yet to be placed on the EU market. The scheme aims to support medicinal products of major public health interest and in particular from the viewpoint of therapeutic innovation. Medicines eligible for PRIME must address an unmet medical need, i.e. for which there exists no satisfactory method of diagnosis, prevention or treatment in the Community or, if such a method exists, in relation to which the medicinal product concerned will be of major therapeutic advantage to those affected. A product eligible for PRIME should demonstrate the potential to address, to a significant extent, the unmet medical need, for example by introducing new methods of therapy or improving existing ones. Data available to support the request for eligibility should support the claim to address the unmet medical need through a clinically meaningful improvement of efficacy, such as having an impact on the prevention, onset or duration of the condition, or improving the morbidity or mortality of the disease. EMA will provide early and enhanced support to optimize the development of eligible medicines. Products granted PRIME support are anticipated to benefit from the Accelerated Assessment procedure. More information about the qualifying criteria and features of PRIME and Accelerated Assessment can be found on the EMA’s website.

- **Regenerative Medicine Advanced Therapy (RMAT) (U.S.)** is a designation that is granted to regenerative medicine therapies intended to treat, modify, reverse, or cure a serious condition, for which preliminary clinical evidence indicates that the medicine has the potential to address an unmet medical need. The RMAT designation includes all the benefits of the fast track and breakthrough therapy designation programs, including early interactions with FDA.